Experimental design v1
Year: 2020
Type: preprint
Abstract: Experimental design Neonatal treatment: Balb/c mice offspring were exposed to intranasal applications on day 3 after birth and subsequently on every other day up to 13 days of life. While one group of animals were treated with PBS, the other received 1μg/5μl of LPS (Escherichia coli O55:B5 Sigma-Aldrich; St. Louis, MO, USA) according to protocols optimized for volume, treatment timing, and according to evidence indicating that this dosis induces antigen-specific Th1 responses and previous studies. Allergen sensitization in weaned animals: At the age of 4 weeks, animals were sensitized by subsequent i.p injections of 0.1 ml of Ovalbumin (OVA) grade VI (100 µg/100 μl, Sigma-Aldrich) absorbed to 1 mg of inject Alum (Pierce Rockford, USA) on the 4th and 6th weeks of life. Airway challenge in puberty and adulthood: Ten days later (7h weeks of life), neonatally (n) LPS-treated mice as well as PBS-exposed ones were divided into 2 groups. Whereas the LPSn/OVA and PBSn/OVA mice were challenged daily (on 10 consecutive days) by an intranasal application of 50μl of 1% OVA, the LPSn and PBSn mice were submitted to an intranasal application of saline (Fig 1a). Then, after 24h, at 9h weeks of life, mice were sacrificed and processed according to the specific methods outlined below.
Author: Luciana Garcia
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4236415786